2025 EVENT SITE
WMIF MAIN SITEMark C. McKenna is the founder, Chairman, and CEO of Mirador Therapeutics, and a renowned biotech entrepreneur, executive, and director known for his exceptional leadership and visionary approach.
Mr. McKenna served as Chairman, President, and CEO of Prometheus Biosciences from 2019 until its acquisition by Merck for $10.8 billion in June 2023. Under his leadership, Prometheus raised over $1 billion in private and public financing, was recognized as the top-performing biotech IPO of 2021, and pioneered the first precision therapeutics clinical trial for immune-mediated diseases. This led to its acquisition by Merck, resulting in the largest buyout of company with a pre-Phase 3 asset to date.
Prior to Prometheus, Mr. McKenna was the President of Salix Pharmaceuticals and a corporate officer at Bausch + Lomb. There, he revitalized the gastroenterology business through strategic acquisitions and product launches, doubling revenue to over $2 billion and significantly enhancing operating margins. He also spent over a decade at Bausch + Lomb, where he was SVP and General Manager of the US Vision Care business.
Mr. McKenna began his career at Johnson & Johnson, where he held several positions of increasing responsibility. He currently serves as the Chairman of Apogee Therapeutics, Inc. (Nasdaq: APGE) and is a board member of Spyre Therapeutics, Inc. (Nasdaq: SYRE). In 2023, he was honored as Ernst & Young Entrepreneur of the Year.
Mr. McKenna holds a B.S. in marketing from Arizona State University and an MBA from Azusa Pacific University.
Chairman & CEO, Mirador Therapeutics
Join our email list to receive exclusive offers